Medical Devices industry cross border deals total $6.9bn globally in Q2 2022

ArchiMed’s $1.2bn private equity deal with Natus Medical was the Medical devices industry’s biggest cross border deal of Q2 2022 as cross border deals worth $6.9bn were announced globally in the quarter, according to GlobalData’s deals database.

The value marked an increase of 1.9% over the previous quarter and a drop of 44.7% when compared with the last four-quarter average of $12.52bn.

In terms of number of cross border deals, the sector saw a drop of 16.28% with 153 deals in Q2 2022 against the average of 182.75 deals in the last four-quarters.

In value terms, Europe led the activity with cross border deals worth $3.5bn.

Medical devices industry cross border deals in Q2 2022: Top deals

The top five Medical devices industry cross border deals accounted for 55.5% of the overall value during Q2 2022.

The combined value of the top five cross border deals stood at $3.84bn, against the overall value of $6.9bn recorded for the quarter.

The top five Medical devices industry cross border deals of Q2 2022 tracked by GlobalData were:

1) ArchiMed $1.2bn private equity deal with Natus Medical

2) The $1bn acquisition of MediFox DAN Group by ResMed

3) EQT IX Fund $797.86m private equity deal with SPT Labtech

4) The $541.63m acquisition of Phenox by Wallaby Medical

5) CVS Health,Export Development Bank of Iran,General Atlantic,Mass Mutual Ventures,Openspace Ventures,Sequoia Capital and SoftBank Vision Fund II $300m venture financing deal with Biofourmis